Ovarian reserve after treatment with alkylating agents during childhood | Zendy

Cécile ThomasTeinturier | Zendy; Rodrigue S. Allodji | Zendy; Ekaterina Svetlova | Zendy; Marie-Alix Frey | Zendy; Odile Oberlin | Zendy; A. Millischer | Zendy; Sylvie Epelboin | Zendy; Christine Decanter | Zendy; Hélène Pacquement | Zendy; MarieDominique Tabone | Zendy; Hélène SudourBonnange | Zendy; André Baruchel | Zendy; Najiba Lahlou | Zendy; Florent de Vathaire | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ovarian reserve after treatment with alkylating agents during childhood

Author(s) -

Cécile ThomasTeinturier,

Rodrigue S. Allodji,

Ekaterina Svetlova,

Marie-Alix Frey,

Odile Oberlin,

A. Millischer,

Sylvie Epelboin,

Christine Decanter,

Hélène Pacquement,

MarieDominique Tabone,

Hélène SudourBonnange,

André Baruchel,

Najiba Lahlou,

Florent de Vathaire

Publication year - 2015

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/dev060

Subject(s) - ovarian reserve , procarbazine , antral follicle , medicine , luteinizing hormone , anti müllerian hormone , ovary , cyclophosphamide , hormone , fertility preservation , chemotherapy , oncology , endocrinology , gynecology , fertility , pregnancy , population , biology , vincristine , infertility , genetics , environmental health

What is the effect of different alkylating agents used without pelvic radiation to treat childhood cancer in girls on the ovarian reserve in survivors?

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research